B vitamins may reduce stroke risk: Meta-analysis

By Stephen Daniells

- Last updated on GMT

B vitamins may reduce stroke risk: Meta-analysis

Related tags: Cardiovascular disease, Folic acid

Supplements of B vitamins may reduce the risk of stroke by about 12%, according to a new meta-analysis published in Clinical Nutrition.

Despite the positive link to stroke risk, data from 19 randomized controlled trials involving 47,921 participants suggested no benefits for B vitamin supplementation on the risk of cardiovascular disease (CVD), coronary heart disease or heart attack.

The meta-analysis represents the “most recent information available on the associations between B vitamins supplementations and risk of CVD”​, said researchers from Zhejiang University in China, the National Health Research Institutes in Taiwan, and Monash University in Australia.

Controversy

The potential role of B vitamins in heart health, by reducing levels of the amino acid homocysteine reported to increase the risk of cardiovascular disease, is controversial.

Epidemiological studies have linked increased blood levels of the amino acid homocysteine to an increased risk of cardiovascular disease (CVD). It has been suggested that by lowering the levels of homocysteine in the blood with B-vitamins, people could cut the risk of CVD.

However, clinical trials including participants at risk of, or already suffering from, cardiovascular disease have produced null results, with some experts arguing that short term B vitamin supplementation should not be expected to reverse the long-term development of heart disease.

In 2009 a prestigious Cochrane review concluded in that supplements of B6, B12 or folate do not affect cardiovascular health, despite lowering homocysteine levels. The review included data from eight randomized controlled trials equivalent to 24,210 participants.

New data

While the new meta-analysis agrees that B vitamins did not affect the risk of cardiovascular disease (CVD), coronary heart disease or heart attack, it does challenge the conclusions regarding stroke risk.

Nineteen studies provided data obtained from intervention and follow-up periods ranging from 6 to 85 months, and doses of folic acid with or without vitamins B6 and B12.

Results showed that B vitamin supplementation was associated with significant reductions in homocysteine levels, and a 12% reduction in the risk of stroke, compared with placebo, but no differences were observed for other cardiovascular outcomes.

“The discrepancies between the RCTs of B vitamins supplementation for the prevention of CVD may have various explanations,”​ said the researchers.

“First, it is possible that populations without folate deficiency may not benefit from folic acid supplementation

“Second, RCTs may not avoid residual confounding. Different personal behaviors may modify the effects of dietary intake or supplement use on vascular disease. Then, the duration of follow-up and sample size may also contribute to differences between clinical trials.

“Third, trials to date have examined the effects of B vitamin supplementation for secondary prevention only.”

Source: Clinical Nutrition
Published online ahead of print, doi: 10.1016/j.clnu.2011.01.003
“Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality”
Authors: T. Huang, Y. Chen, B. Yang, J. Yang, M.L. Wahlqvist, D. Li

Related news

Show more

Related products

show more

Resveratrol and Sports Nutrition: A Winning Combo

Resveratrol and Sports Nutrition: A Winning Combo

Evolva | 18-Oct-2019 | Technical / White Paper

In addition to physical activity, research indicates that resveratrol can be a key ingredient for top sports performance. Not only has resveratrol been...

Vitamin K2 Success Stories: NattoPharma

Vitamin K2 Success Stories: NattoPharma

NattoPharma USA, Inc. | 23-Sep-2019 | Case Study

Partnership means companies are bound to the process – from formulation and testing to marketing and meeting demand. That is what companies selecting MenaQ7®...

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals | 01-Sep-2019 | Application Note

The industry has shown improvement in its transparency in the past 5 years. Per the regulations, a Brand Owner is 100% responsible for the quality of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars